Leucadia National - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 44 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.8%.

Quarter-by-quarter ownership
Leucadia National ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q2 2023$4,783,239
+220.8%
93,789
+34.5%
0.04%
+258.3%
Q1 2023$1,491,161
+109.9%
69,713
+3.0%
0.01%
+140.0%
Q4 2022$710,36767,6540.01%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q1 2023
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders